



International Journal of Research Publication and Reviews

Journal Homepage: www.ijrpr.com ISSN 2582-7421

Caplan Syndrome: Current Insights into Pathogenesis, Clinical Manifestations, Diagnosis, And Emerging Therapeutic Strategies

Annarapu Sriramteja, Syeda Nishat Fathima

Department of Pharmacology, Jayamukhi College of Pharmacy, Narsampet, Warangal-506332, Telangana, India

Email: annarapu.sriramteja1025@gmail.com

DOI : <https://doi.org/10.55248/gengpi.07.1026.3215>

ABSTRACT:

Caplan syndrome, also known as rheumatoid pneumoconiosis, is a rare occupational lung disease characterized by the coexistence of rheumatoid arthritis, pneumoconiosis, and multiple pulmonary nodules following prolonged exposure to coal dust, silica, or other mineral particulates. The syndrome exemplifies the interplay between environmental exposure and autoimmune mechanisms, involving macrophage activation, inflammasome signaling, protein citrullination, autoantibody production, and chronic inflammation. Clinically, patients present with cough, dyspnea, chest discomfort, or incidental radiographic findings, while diagnosis relies on occupational history, serological markers, characteristic imaging, and exclusion of infections, malignancy, and other pulmonary disorders. Management focuses on eliminating dust exposure, smoking cessation, disease-modifying antirheumatic therapy, pulmonary rehabilitation, and multidisciplinary care to preserve lung function and control rheumatoid disease. Emerging research on cytokine-targeted therapies, antifibrotic agents, and biomarker-guided diagnosis offers promising therapeutic opportunities. This review summarizes the epidemiology, pathogenesis, clinical features, diagnosis, differential diagnosis, current management strategies, and future research directions of Caplan syndrome.

Keywords: Caplan syndrome; Rheumatoid pneumoconiosis; Rheumatoid arthritis; Pneumoconiosis; Silica exposure; Coal dust; Occupational lung disease; Pulmonary nodules

INTRODUCTION

Caplan syndrome occupies an important niche at the interface of occupational medicine, pulmonology, rheumatology, and pharmacology. The syndrome classically refers to the occurrence of multiple well-defined pulmonary nodules in a patient with rheumatoid arthritis and concurrent pneumoconiosis, especially coal workers' pneumoconiosis or silicosis. Historically, it was described among coal miners who developed characteristic radiologic lesions distinct from the simple fibrotic changes of dust exposure alone. Over time, the syndrome has also been associated with exposure to silica and mixed mineral dusts, extending its relevance beyond coal mining to a broader range of occupational environments.

The enduring significance of Caplan syndrome lies in its value as a model of environmentally triggered autoimmunity. It illustrates how inhaled particulates can do more than injure lung parenchyma mechanically or fibrogenically; they can also alter antigen processing, amplify inflammatory cascades, and contribute to systemic immune activation. This concept has become increasingly important in rheumatoid arthritis research, where pulmonary mucosal immune responses are now thought to precede or shape articular disease in at least a subset of patients. Caplan syndrome therefore offers a uniquely visible example of the lung as a potential site of autoimmune initiation and propagation. [1]

From a clinical perspective, Caplan syndrome presents diagnostic and therapeutic challenges. Pulmonary nodules in a patient with rheumatoid arthritis raise concern for infection, malignancy, vasculitis, methotrexate-associated nodulosis, and other inflammatory conditions. Likewise, respiratory symptoms in dust-exposed individuals may reflect chronic obstructive pulmonary disease, interstitial fibrosis, tuberculosis, hypersensitivity phenomena, or progressive massive fibrosis rather than Caplan syndrome itself. Accurate diagnosis requires integration of imaging, serology, occupational exposure history, and clinicopathologic judgment. From a pharmacologic standpoint, management is equally nuanced. No therapy specifically reverses Caplan nodules, and treatment decisions must balance suppression of rheumatoid inflammation against pulmonary safety, infection risk, fibrotic progression, and the patient's environmental exposure burden. Some disease-modifying antirheumatic drugs have been implicated in pulmonary adverse effects or accelerated nodulosis, while biologic therapies offer potential benefits yet demand careful patient selection. These realities make Caplan syndrome a compelling subject for contemporary review.

This article examines current insights into the pathogenesis, clinical manifestations, diagnosis, differential diagnosis, and emerging therapeutic strategies for Caplan syndrome. It also highlights unresolved questions, especially regarding causation, biomarkers, optimal pharmacologic management, and future avenues for preventive and translational research.

HISTORICAL BACKGROUND AND DEFINITION:

Caplan syndrome, also known as rheumatoid pneumoconiosis, was first described by Anthony Caplan in the 1950s after observing a distinctive pattern of pulmonary nodules in coal miners with rheumatoid arthritis (RA). Unlike the diffuse fibrotic changes typical of pneumoconiosis, these lesions were multiple, well-defined, rounded nodules that developed rapidly and were predominantly located in the peripheral regions of the lungs. Histopathological examination revealed features similar to rheumatoid nodules, including central fibrinoid necrosis surrounded by palisading histiocytes and inflammatory cells within dust-laden pulmonary tissue. The syndrome is classically characterized by the coexistence of RA, occupational dust-induced pneumoconiosis, and characteristic pulmonary nodules. Although the term was initially restricted to coal workers, it is now broadly applied to dust-exposed individuals with RA who develop similar pulmonary lesions, particularly following exposure to silica or coal dust. Variability in diagnostic criteria has contributed to uncertainty regarding its true prevalence. While improved occupational safety measures have reduced the incidence of severe pneumoconiosis, Caplan syndrome continues to occur among workers in mining, construction, stone cutting, foundries, tunneling, ceramics, and sandblasting industries. Because clinicians now encounter classical pneumoconiosis less frequently, the syndrome may be underdiagnosed or mistaken for malignancy, infectious lung disease, or rheumatoid-associated interstitial lung disease. [2]

EPIDEMIOLOGY AND RISK FACTORS

Caplan syndrome is rare relative to both rheumatoid arthritis and pneumoconiosis individually. Its exact prevalence is difficult to establish because of changing occupational patterns, inconsistent definitions, and underreporting. Earlier literature suggested a higher burden among coal miners with rheumatoid arthritis, but modern epidemiologic estimates vary widely. The syndrome appears more common in men because of historical occupational distribution, though this sex imbalance may narrow as workforce patterns change. [3]

The two principal disease substrates are occupational dust exposure and rheumatoid autoimmunity. Coal dust and crystalline silica are the most strongly implicated inhaled agents. Silica deserves particular emphasis because of its well-established association with autoimmune disease, including rheumatoid arthritis, systemic sclerosis, and ANCA-associated vasculitis. Silica particles can persist in lung tissue for prolonged periods, perpetuating macrophage injury and inflammatory signaling. Mixed dust exposure may similarly contribute, especially when respirable particle loads are high and long-standing.

Smoking is another relevant risk factor. In rheumatoid arthritis, smoking promotes citrullination and anti-citrullinated protein antibody formation, especially in genetically susceptible individuals. When combined with mineral dust exposure, smoking may intensify pulmonary inflammation and lower the threshold for autoimmunity. Not all patients with Caplan syndrome are smokers, but tobacco exposure plausibly acts as a cofactor in disease development and progression.

Genetic susceptibility also appears important. Although data specific to Caplan syndrome are limited, rheumatoid arthritis susceptibility alleles, particularly HLA-DRB1 shared epitope variants, are known to interact with environmental exposures such as smoking to heighten risk of seropositive disease. It is reasonable to infer a similar gene-environment interaction in Caplan syndrome, wherein dust-driven pulmonary immune activation converges with host predisposition to produce autoantibody-rich systemic inflammation.

Additional factors may include duration and intensity of occupational exposure, inadequate protective equipment, coexisting chronic lung disease, delayed diagnosis of rheumatoid arthritis, and high autoantibody titers. Seropositive rheumatoid arthritis, especially with rheumatoid factor and anti-cyclic citrullinated peptide positivity, seems particularly associated with extra-articular disease, including nodulosis. In some patients, pulmonary nodules may even precede overt joint manifestations, reinforcing the notion that autoimmune processes may begin in the lung.

PATHOGENESIS: CURRENT INSIGHTS

The pathogenesis of Caplan syndrome is complex and likely multifactorial. A unifying model must account for three linked processes: inhalational lung injury from occupational particulate exposure, generation or amplification of rheumatoid autoimmunity, and localized formation of necrobiotic pulmonary nodules. [4,5]

Dust-Induced Pulmonary Inflammation: Respirable coal dust and silica particles deposit in terminal airways and alveoli, where they are engulfed by alveolar macrophages. Silica is especially cytotoxic; it destabilizes lysosomes, triggers reactive oxygen species production, and activates the NLRP3 inflammasome. This leads to release of proinflammatory mediators such as interleukin-1 beta, interleukin-18, tumor necrosis factor-alpha, and transforming growth factor-beta. Repeated exposure sustains macrophage activation, recruits neutrophils and lymphocytes, and promotes fibrogenic remodeling. Coal dust, though somewhat less directly cytotoxic than crystalline silica, can still induce chronic inflammation, oxidative stress, and deposition of dust-laden macrophages within the lung interstitium. Over time, the resulting tissue injury creates a microenvironment conducive to aberrant antigen presentation and chronic immune stimulation.

Citrullination and Autoantibody Generation: One of the most compelling mechanistic links between inhaled dust and rheumatoid arthritis is the promotion of protein citrullination, a post-translational modification catalyzed by peptidylarginine deiminase enzymes. Inflamed lung tissue, especially in smokers and dust-exposed individuals, may generate citrullinated self-proteins that are recognized as neoantigens in genetically susceptible hosts. These antigens may then drive formation of anti-citrullinated protein antibodies, a hallmark of seropositive rheumatoid arthritis. The lung has been

proposed as a key site for the initiation of rheumatoid autoimmunity. In this framework, occupational dust exposure acts as a persistent mucosal insult, enhancing antigen modification, dendritic cell activation, and local lymphoid aggregation. Autoantibodies produced or amplified in the pulmonary compartment may later contribute to systemic synovial inflammation, or parallel immune processes may emerge in both lung and joints.

Rheumatoid Nodule Formation in the Lung: The pulmonary nodules of Caplan syndrome resemble rheumatoid nodules seen subcutaneously and in other extra-articular sites. Histologically, these nodules typically contain a central zone of fibrinoid necrosis, surrounded by palisading macrophages and fibroblasts, with an outer rim of chronic inflammatory infiltrate that may include lymphocytes and plasma cells. In Caplan syndrome, this architecture occurs in lungs already altered by dust deposition and pneumoconiotic change. Immune complex deposition, local vasculopathy, macrophage activation, and cytokine-driven granuloma-like organization may all contribute to nodule formation. Tumor necrosis factor- α , interleukin-1, interleukin-6, and other mediators of rheumatoid inflammation likely participate. Repeated tissue injury may encourage a cycle of necrosis and repair, leading to the rapid appearance of multiple nodules. Some nodules cavitate or calcify, and others may wax and wane independent of articular disease activity.

Fibrosis, Vascular Injury, and Immune Amplification: Although pulmonary nodules are the signature lesion, Caplan syndrome may coexist with other pulmonary abnormalities such as interstitial fibrosis, emphysema, chronic bronchitis, and progressive massive fibrosis attributable to the underlying pneumoconiosis or rheumatoid lung disease. Fibrogenic cytokines, oxidative stress, epithelial injury, and endothelial dysfunction may amplify each other, creating a continuum between nodular inflammation and chronic structural lung damage. An additional possibility is that dust exposure acts not simply as a trigger but as an adjuvant, enhancing immune responses to self-antigens. Silica in particular has been implicated in disruption of immune tolerance, apoptosis dysregulation, and prolonged survival of autoreactive lymphocytes. This broader immunotoxic effect may explain why autoimmune manifestations in exposed workers can extend beyond classic Caplan syndrome.

Pharmacologic Implications of Pathogenesis: Understanding pathogenesis has direct therapeutic implications. If inflammatory cytokine networks, macrophage activation, and autoimmune amplification are central drivers, then targeted immunomodulatory strategies may have mechanistic value. Conversely, if fibrotic remodeling predominates in certain patients, anti-inflammatory therapy alone may be insufficient. The challenge is that current evidence remains largely descriptive, and robust trials specific to Caplan syndrome are lacking. Nevertheless, a pathogenesis-based approach can inform individualized care and future drug development.

CLINICAL MANIFESTATIONS

The clinical presentation of Caplan syndrome is variable. Some patients are asymptomatic and diagnosed incidentally during imaging for occupational surveillance or rheumatoid disease evaluation. Others present with respiratory symptoms, articular manifestations, constitutional complaints, or complications related to cavitary nodules or advanced pneumoconiosis. [6,7]

Respiratory Features: Common respiratory symptoms include chronic cough, exertional dyspnea, sputum production, chest discomfort, and reduced exercise tolerance. These manifestations may be caused by the nodules themselves, coexisting dust-related lung disease, chronic airway disease, or rheumatoid-associated interstitial involvement. Hemoptysis is less common but may occur with cavitation, superimposed infection, or other pulmonary pathology. In many patients, symptoms are nonspecific and cannot be attributed to Caplan nodules alone. Physical examination may be unrevealing in early disease. Depending on associated pulmonary abnormalities, patients may exhibit crackles, wheeze, prolonged expiration, digital clubbing, or signs of chronic hypoxemia in advanced cases. Respiratory compromise is often more reflective of concomitant pneumoconiosis, chronic obstructive pulmonary disease, or fibrotic lung disease than of the nodules themselves.

Articular and Extra-Articular Features: Most patients have established rheumatoid arthritis characterized by symmetric inflammatory polyarthritis involving small joints of the hands and feet, morning stiffness, swelling, tenderness, and progressive functional limitation. Seropositive disease is common, and extra-articular manifestations such as subcutaneous rheumatoid nodules, fatigue, anemia of chronic inflammation, vasculitic features, and ocular involvement may coexist. In some cases, pulmonary nodules precede the formal diagnosis of rheumatoid arthritis. Such patients may initially be identified through chest radiography abnormalities in the context of occupational exposure, only later developing overt synovitis or serologic confirmation. This sequence reinforces the hypothesis that pulmonary immune events may predate clinically evident joint disease.

Radiologic and Temporal Pattern: A classic feature of Caplan syndrome is the relatively sudden appearance of multiple rounded pulmonary nodules, often peripheral and well-defined, measuring from a few millimeters to several centimeters. These may occur against a background of simple pneumoconiosis. Lesions can remain stable, enlarge, cavitate, calcify, or occasionally regress. New nodules may appear over time, and radiologic progression does not always parallel joint disease activity.

Complications: Complications include cavitation with secondary infection, pneumothorax in rare cases, progressive respiratory impairment, and diagnostic confusion leading to invasive procedures. The presence of rheumatoid arthritis and immunosuppressive therapy may also increase susceptibility to tuberculosis, nontuberculous mycobacterial infection, and fungal disease, all of which can mimic or complicate Caplan syndrome. Patients with significant silica exposure may carry an especially heightened risk for tuberculosis, making exclusion of infection a critical part of assessment.

DIAGNOSTIC EVALUATION:

Diagnosis of Caplan syndrome is clinical-radiologic and relies on synthesis rather than a single definitive test. A careful, structured workup is essential. [8]

Occupational and Clinical History: The cornerstone of diagnosis is a detailed occupational exposure history. Clinicians should document the type of work, duration of exposure, tasks generating respirable dust, use of respiratory protection, workplace controls, and latency between exposure and symptom onset. History of coal mining, stone cutting, sandblasting, quarrying, tunneling, ceramics, foundry work, and construction is especially relevant. Smoking history should also be assessed carefully. The clinician should evaluate the duration, activity, and serologic status of rheumatoid arthritis; prior disease-modifying antirheumatic drug use; extra-articular disease; and symptoms suggesting alternative diagnoses such as fever, weight loss, purulent sputum, night sweats, or malignancy-related symptoms.

Laboratory Investigations: Serologic testing typically includes rheumatoid factor and anti-cyclic citrullinated peptide antibodies, both of which are often positive. Elevated inflammatory markers such as erythrocyte sedimentation rate and C-reactive protein may reflect rheumatoid activity but are nonspecific. Complete blood count, liver and renal function tests, and autoimmune screening may help contextualize systemic disease and treatment planning. Where clinically indicated, evaluation should also include tuberculosis testing, fungal serologies, blood cultures in febrile patients, and ANCA or other autoimmune assays when vasculitis is a concern. Biomarkers specific to Caplan syndrome are not yet established, though future research may identify profiles reflecting citrullination burden, macrophage activation, or pneumoconiotic inflammation.

Imaging: Chest radiography historically played a major role and may reveal multiple round, well-circumscribed opacities, often in the lung periphery and superimposed on background pneumoconiotic change. However, high-resolution computed tomography is now central to modern evaluation because it better characterizes nodule number, distribution, cavitation, calcification, associated fibrosis, emphysema, and mediastinal lymphadenopathy.

Computed tomography may show:

- Multiple bilateral peripheral nodules of variable size
- Background simple pneumoconiosis or silicotic nodules
- Cavitation within some lesions
- Coexisting interstitial abnormalities
- Progressive massive fibrosis or emphysema in advanced dust-related lung disease

Imaging alone cannot definitively distinguish Caplan nodules from malignancy, septic emboli, granulomatous infection, or rheumatoid nodules unrelated to pneumoconiosis. Nevertheless, the combination of occupational exposure, rheumatoid autoimmunity, and compatible radiologic pattern can be highly suggestive.

Pulmonary Function Testing: Pulmonary function tests may be normal or may show obstructive, restrictive, or mixed defects depending on the burden of coexisting lung disease. Reduced diffusing capacity may occur in interstitial involvement or emphysema. While not diagnostic, pulmonary function testing provides a baseline for monitoring severity and progression.

Bronchoscopy and Tissue Diagnosis: Bronchoscopy may be considered when infection, malignancy, or alternative pathology must be excluded. Bronchoalveolar lavage can assist in microbiologic evaluation. Tissue biopsy, obtained bronchoscopically, percutaneously, or surgically, is not required in every patient but may be necessary when imaging is atypical, nodules are solitary or enlarging, or diagnostic uncertainty persists. Histopathology usually reveals rheumatoid-type necrobiotic nodules within dust-laden lung tissue. The central necrosis may be surrounded by palisading histiocytes, fibroblasts, chronic inflammatory cells, and pneumoconiotic pigment. Because infection and malignancy can coexist, histologic interpretation should always be integrated with microbiology and clinical context.

DIFFERENTIAL DIAGNOSIS:

The differential diagnosis of pulmonary nodules in a patient with rheumatoid arthritis and occupational exposure is broad and clinically significant. [9]

Infectious Causes: Tuberculosis is a major consideration, particularly in silica-exposed workers and immunosuppressed patients. Nontuberculous mycobacterial infection and fungal diseases such as histoplasmosis, aspergillosis, and cryptococcosis may also present with nodules or cavitary lesions. Septic emboli should be considered in patients with fever, bacteremia, endocarditis risk, or acute systemic illness.

Malignancy: Primary lung carcinoma and metastatic disease must be excluded, especially in smokers, older patients, or those with solitary, enlarging, spiculated, or PET-avid lesions. Pneumoconiosis itself may coexist with malignancy, and rheumatoid arthritis does not eliminate oncologic risk. Tissue confirmation is often required when the imaging pattern is not classic.

Other Rheumatoid Lung Manifestations: Rheumatoid arthritis can cause pulmonary nodules even without pneumoconiosis, as well as interstitial lung disease, organizing pneumonia, bronchiolitis, pleural disease, and drug-related pulmonary toxicity. Methotrexate, leflunomide, and some biologic

agents may complicate interpretation by causing or exacerbating lung findings in certain settings. Accelerated nodulosis is a recognized phenomenon in rheumatoid disease and may mimic Caplan syndrome when exposure history is incomplete.

Autoimmune and Vasculitic Conditions: Granulomatosis with polyangiitis, rheumatoid vasculitis, sarcoidosis, and other inflammatory diseases can present with nodules or cavitation. Serologic testing and systemic clinical features help narrow the diagnosis, but overlap can occur.

Occupational Lung Disease Without Caplan Syndrome: Simple pneumoconiosis, silicosis, and progressive massive fibrosis may produce nodular or mass-like radiographic findings. Distinguishing these from Caplan nodules depends on the presence of rheumatoid autoimmunity, nodule morphology, and sometimes histology.

THERAPEUTIC STRATEGIES

Management of Caplan syndrome is individualized and generally focuses on five parallel goals: removal from harmful exposure, control of rheumatoid inflammation, preservation of lung function, treatment of complications, and avoidance of medication-related pulmonary harm. Because no randomized controlled trials define a disease-specific standard of care, treatment is largely extrapolated from rheumatoid arthritis, pneumoconiosis, and related pulmonary disorders. [10,11]

Exposure Cessation and Preventive Measures: The first and most fundamental intervention is cessation or minimization of further dust exposure. Continued inhalation may perpetuate inflammation, worsen pneumoconiosis, and sustain antigenic stimulation. Occupational reassignment, engineering controls, dust suppression, improved ventilation, and properly fitted respiratory protection are important. Smoking cessation is equally critical, given its role in pulmonary injury and rheumatoid autoimmunity. Vaccination against influenza, pneumococcus, and other relevant respiratory pathogens should be optimized, especially in patients receiving immunosuppressive therapy. Pulmonary rehabilitation and exercise conditioning may be beneficial for symptomatic individuals with impaired functional capacity.

Pharmacologic Management of Rheumatoid Arthritis: Control of systemic rheumatoid inflammation is central to therapy. Conventional disease-modifying antirheumatic drugs such as methotrexate, sulfasalazine, hydroxychloroquine, and leflunomide are standard agents in rheumatoid arthritis, but their use in Caplan syndrome requires pulmonary caution.

- Methotrexate is widely effective for rheumatoid arthritis, yet pulmonary considerations complicate its use. Methotrexate-associated pneumonitis, though uncommon, is a recognized adverse effect, and methotrexate has also been associated with accelerated nodulosis in some patients. This does not make methotrexate universally contraindicated in Caplan syndrome, but it does warrant careful baseline lung assessment, patient education, and vigilance for new respiratory symptoms.
- Leflunomide has been linked to interstitial lung toxicity, particularly in patients with preexisting lung disease. Its use should therefore be individualized and monitored cautiously. Hydroxychloroquine and sulfasalazine may be considered in selected patients, especially when a safer pulmonary profile is desired, though efficacy for severe rheumatoid disease may be limited when used alone.
- Systemic glucocorticoids may help suppress inflammatory activity during disease flares or when nodules are associated with symptomatic inflammatory lung involvement. However, their long-term use is limited by substantial adverse effects, including infection risk, osteoporosis, diabetes, hypertension, myopathy, and adrenal suppression. In patients with possible tuberculosis or fungal exposure, corticosteroids should be used judiciously and only after adequate infectious evaluation. Short-term courses may be reasonable in selected cases, but steroid-sparing strategies are preferable.
- Biologic therapies targeting tumor necrosis factor- α , interleukin-6, B cells, or T-cell costimulation have transformed rheumatoid arthritis management. Their role in Caplan syndrome is promising but incompletely defined. Control of systemic inflammatory burden may theoretically reduce extra-articular manifestations, but biologics also carry pulmonary and infectious risks.
- TNF inhibitors may benefit rheumatoid arthritis activity, yet their use in patients with preexisting pulmonary nodules requires caution because of infection risk, particularly tuberculosis, and variable effects on nodulosis. Some reports suggest worsening or emergence of rheumatoid nodules under certain biologic therapies, while others document stabilization. The evidence is inconsistent.
- Rituximab, a B-cell-depleting agent, may be attractive in seropositive extra-articular rheumatoid disease and in patients with interstitial lung involvement where some clinicians prefer it over TNF inhibitors. Abatacept and tocilizumab may also be considered based on overall rheumatoid disease profile, comorbidity burden, and prior treatment response. Janus kinase inhibitors represent another option, though concerns about infection, thrombotic risk, and limited lung-specific evidence warrant individualized decision-making.

In practice, therapeutic selection should be multidisciplinary, involving rheumatology and pulmonology. The clinician must weigh articular control, pulmonary reserve, risk of latent or active infection, radiographic pattern, and prior drug tolerance.

Management of Pulmonary Complications: Specific treatment of Caplan nodules is often conservative when lesions are stable and asymptomatic. Serial imaging may suffice. Cavitory lesions require evaluation for superimposed infection. Antibiotic or antifungal therapy should be guided by microbiologic evidence rather than empiric prolonged use without diagnosis. For patients with coexisting chronic obstructive airway disease, bronchodilators and inhaled therapies may improve symptoms. Oxygen therapy may be needed in advanced respiratory insufficiency. Pulmonary rehabilitation can improve exercise capacity and quality of life, even though it does not alter the nodules directly. If progressive fibrosis or interstitial

lung disease is present, treatment becomes more complex. The possible role of antifibrotic agents such as nintedanib in progressive fibrosing phenotypes associated with autoimmune lung disease is of growing interest. Although not established specifically for Caplan syndrome, this therapeutic concept may become relevant for selected patients with progressive fibrotic behavior.

Surgical Considerations: Surgery is rarely indicated for Caplan syndrome itself but may be necessary for diagnostic biopsy, persistent suspicion of malignancy, complicated cavitory lesions, or recurrent pneumothorax. Operative risk can be substantial in patients with poor pulmonary reserve and should be assessed carefully.

EMERGING THERAPEUTIC STRATEGIES AND RESEARCH DIRECTIONS

The future management of Caplan syndrome will likely be shaped by advances in immunology, exposure science, imaging analytics, and precision therapeutics. [12]

Cytokine-Targeted and Immune-Modifying Therapies: As the roles of tumor necrosis factor-alpha, interleukin-1, interleukin-6, and inflammasome pathways become clearer, more rational targeted interventions may emerge. If silica-induced inflammasome activation proves central in susceptible patients, inhibitors of upstream innate immune signaling could become therapeutically relevant. Similarly, strategies that interrupt citrullination, autoantigen presentation, or B-cell-mediated autoantibody production may have preventive or disease-modifying value.

Biomarker Development: A major unmet need is the identification of biomarkers that distinguish Caplan syndrome from other pulmonary nodular disorders and predict disease course. Potential candidates include anti-citrullinated protein antibody profiles, bronchoalveolar lavage immune signatures, cytokine panels, extracellular vesicle markers, and imaging-radiomic correlates. Biomarkers could also help determine whether a patient's dominant process is inflammatory, fibrotic, infectious, or neoplastic.

Antifibrotic Approaches: Because many patients with Caplan syndrome have overlapping fibrotic lung injury from pneumoconiosis or rheumatoid-associated interstitial disease, antifibrotic therapy is an area of interest. Better phenotyping is needed to identify who may benefit from agents developed for progressive pulmonary fibrosis. Future studies should assess whether combined immunomodulatory and antifibrotic regimens improve outcomes in mixed inflammatory-fibrotic phenotypes.

Occupational Prevention as Therapy Upstream: Perhaps the most effective “emerging strategy” is improved prevention. Reducing workplace silica and coal dust exposure through regulatory enforcement, air monitoring, engineering controls, and worker education may decrease both pneumoconiosis and dust-triggered autoimmunity. From a public health and pharmacoeconomic perspective, prevention likely offers greater impact than any downstream drug intervention.

PROGNOSIS:

The prognosis of Caplan syndrome varies according to the severity of underlying pneumoconiosis, rheumatoid disease activity, smoking status, presence of interstitial fibrosis, infection risk, and access to multidisciplinary care. The pulmonary nodules themselves may remain stable or fluctuate without causing major physiologic impairment. However, overall morbidity can be substantial when accompanied by chronic obstructive pulmonary disease, progressive fibrotic lung disease, pulmonary hypertension, recurrent infection, or uncontrolled rheumatoid arthritis. Mortality is generally driven less by the nodules per se than by associated respiratory compromise, cardiovascular comorbidity, infection, and systemic rheumatoid complications. Early recognition, removal from exposure, rigorous monitoring, and individualized therapy can improve clinical outcomes. [13]

CONCLUSION:

Caplan syndrome is a rare but clinically important occupational autoimmune disorder resulting from the interaction between inhaled mineral dust exposure and rheumatoid arthritis, requiring early diagnosis through careful occupational history, clinical evaluation, and appropriate imaging. Although advances in understanding its immunopathogenesis have identified potential therapeutic targets, further research is needed to establish standardized diagnostic criteria, optimize treatment strategies, and strengthen occupational preventive measures to improve patient outcomes.

REFERENCES

1. CAPLAN A. (1953). Certain unusual radiological appearances in the chest of coal-miners suffering from rheumatoid arthritis. *Thorax*, 8(1), 29–37. <https://doi.org/10.1136/thx.8.1.29>
2. Ronsmans, S., & Blanc, P. D. (2023). Colinet-Caplan Syndrome: History of an Outbreak of Autoimmune Disease in Scouring Powder Workers. *Annals of internal medicine*, 176(2), 260–265. <https://doi.org/10.7326/M22-2630>
3. Schreiber, J., Koschel, D., Kekow, J., Waldburg, N., Goette, A., & Merget, R. (2010). Rheumatoid pneumoconiosis (Caplan's syndrome). *European journal of internal medicine*, 21(3), 168–172. <https://doi.org/10.1016/j.ejim.2010.02.004>

4. Laouali, A. M. M., Soumaila, M., Tinni, I. A., Clémence, N. N. T., Rosine, Z. L., Dembélé, O., Dimitri, S., Christèle, E. E., Rahanatou, M., Ouédraogo, I., Kadiatou, B., Giselle, B., & Martial, O. (2026). Caplan Syndrome: A Case Report. *Clinical case reports*, 14(1), e71864. <https://doi.org/10.1002/ccr3.71864>
5. Deepak, J., & Kenaa, B. (2020). Caplan's Syndrome with a twist. *International journal of clinical case reports and reviews : open access*, 2(1), 10.31579/2690-4861/007. <https://doi.org/10.31579/2690-4861/007>
6. De Capitani, E. M., Schwelller, M., Silva, C. M., Metze, K., Cerqueira, E. M., & Bértolo, M. B. (2009). Rheumatoid pneumoconiosis (Caplan's syndrome) with a classical presentation. *Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia*, 35(9), 942–946. <https://doi.org/10.1590/s1806-37132009000900017>
7. Baek, J., & Han, J. Y. (2024). Caplan Syndrome Mimicking Progressive Massive Fibrosis on CT: A Case Report. *Journal of the Korean Society of Radiology*, 85(4), 789–794. <https://doi.org/10.3348/jksr.2023.0128>
8. Xiong, Z., Wu, Y., Tan, J., Chen, X., & Dong, J. (2026). Case Report: The entanglement of infection and autoimmunity: a case of Caplan syndrome. *Frontiers in immunology*, 17, 1715034. <https://doi.org/10.3389/fimmu.2026.1715034>
9. Alfahad, A., Jennings, P., Smith, S., Niktash, N., & Curtin, J. (2015). An interesting finding of multiple calcified pulmonary nodules in a patient with rheumatoid arthritis. *BJR case reports*, 2(1), 20150116. <https://doi.org/10.1259/bjrcr.20150116>
10. Williams, W.J. (1991), CAPLAN'S SYNDROME. *International Journal of Clinical Practice*, 45: 285-288. <https://doi.org/10.1111/j.1742-1241.1991.tb08876.x>
11. Nemakayala, D. R., Surmachevska, N., Vaqar, S., & Ramphul, K. (2024). Caplan Syndrome. In *StatPearls*. StatPearls Publishing.
12. Wang, L., Liu, Y., Zhang, Y., & Hu, Y. (2025). A four-year follow-up of Caplan's syndrome: A case report. *The Journal of international medical research*, 53(6), 3000605251353738. <https://doi.org/10.1177/03000605251353738>
13. Min, Y. S., Kim, M. G., & Ahn, Y. S. (2021). Rheumatoid Arthritis in Silica-Exposed Workers. *International journal of environmental research and public health*, 18(23), 12776. <https://doi.org/10.3390/ijerph182312776>